Endometrial cancer stage II – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:19:40 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Endometrial cancer stage II – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of dostarlimab treatment before surgery in patients with stage II-III endometrial cancer with specific genetic markers https://clinicaltrials.eu/trial/study-of-dostarlimab-treatment-before-surgery-in-patients-with-stage-ii-iii-endometrial-cancer-with-specific-genetic-markers/ Wed, 29 Apr 2026 15:07:22 +0000 https://clinicaltrials.eu/trial/study-of-dostarlimab-treatment-before-surgery-in-patients-with-stage-ii-iii-endometrial-cancer-with-specific-genetic-markers/ This study focuses on patients with endometrial cancer, specifically stage II-III disease with certain genetic characteristics (MMRd/MSI-H). Endometrial cancer is a type of cancer that begins in the lining of the uterus. The study will test a medication called dostarlimab, which is given through an intravenous infusion (delivered directly into a vein).

The purpose of this research is to evaluate how well dostarlimab works when given before surgery (as neoadjuvant therapy) in treating this specific type of endometrial cancer. During the study, participants will receive dostarlimab infusions, with each dose being 500 mg. The treatment may continue for up to 66 weeks, with regular medical check-ups to monitor the patient’s condition.

Throughout the study, doctors will use various imaging tests such as MRI, CT scan, and PET scan to check how the cancer responds to treatment. They will also perform physical examinations and monitor for any side effects. The total amount of dostarlimab that a patient might receive during the entire study period could reach up to 12,000 mg.

]]> Study on Sentinel Lymph Node Mapping Using Gallium-68 Chloride and Tilmanocept in Patients with High-Risk Endometrial Cancer https://clinicaltrials.eu/trial/study-on-sentinel-lymph-node-mapping-using-gallium-68-chloride-and-tilmanocept-in-patients-with-high-risk-endometrial-cancer/ Wed, 29 Apr 2026 14:57:47 +0000 https://clinicaltrials.eu/trial/study-on-sentinel-lymph-node-mapping-using-gallium-68-chloride-and-tilmanocept-in-patients-with-high-risk-endometrial-cancer/ This clinical trial is focused on studying endometrial cancer, which is a type of cancer that begins in the lining of the uterus. The study is specifically looking at patients with high or high-intermediate risk stages of this cancer. The treatment being investigated involves a special imaging technique using a substance called Gallium-68-tilmanocept. This substance is used in a type of scan called PET/CT, which helps doctors see certain areas inside the body more clearly.

The purpose of the study is to see if this imaging method can effectively map the sentinel lymph nodes, which are the first few lymph nodes where cancer is likely to spread. During the study, participants will undergo a PET/CT scan with Gallium-68-tilmanocept to detect these lymph nodes. The study will also compare the results of this scan with another method that uses a different substance called ICG and a special light to see the lymph nodes during surgery.

Throughout the study, researchers will also look at the condition of the lymph nodes to see if they contain cancer cells. They will check for any side effects that might occur from the imaging process. The study aims to provide more information on how well this new imaging technique works for patients with endometrial cancer.

]]>